NSE:ROSSARI management interview: Rossari Biotech Revenue Rises 19% YoY In Q2 | Mgmt Confident Of More Than Doubling Profits In 4 Yrs
CNBC-TV18, 2026-10-19. Video: https://www.youtube.com/watch?v=fgWY7kZEz5Q
- First-half growth: Rossari reported more than 20% growth in both EBITDA and top line in the first half. Exports were ₹221 crore in the latest quarter, supporting better margins than in previous quarters.
- Cash and returns: Management cited cash flows of ₹131 crore and substantial reductions in working-capital days, with a focus on capital preservation and higher asset utilization. ROCE is around 14-15% today, with a target of above 20% in the next 3-4 years.
- Saudi project: The company has begun groundwork and fencing but is waiting for conditions to normalize before investing further; once started, it expects to be ready for production in about 15 months. Management expects turnover and profits to more than double in the next 4 years.
- Growth guidance: Rossari continues to hold its guidance of 10 to 15% growth for the current financial year, while emphasizing positive cash flow and capital preservation.
- Input costs: Management said raw-material increases, including ethylene oxide, have been passed on to customers. B2B EBITDA is now 14% plus, excluding consumer businesses, which are not a focus for the future.